Literature DB >> 24384677

Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.

Hemragul Sabit1, Mitsutoshi Nakada, Takuya Furuta, Takuya Watanabe, Yutaka Hayashi, Hiroshi Sato, Yukinari Kato, Jun-ichiro Hamada.   

Abstract

Glioma, the most common primary brain tumor, is characterized by proliferative-invasive growth. However, the detailed biological characteristics of invading glioma cells remain to be elucidated. A monoclonal antibody (clone HMab-1) that specifically and sensitively recognizes the isocitrate dehydrogenase-1 (IDH1) protein carrying the R132H mutation can identify invading glioma cells by immunostaining. To investigate the degree of invasion in gliomas of distinct grades and the proliferative capacity of the invading cells, immunofluorescent staining was conducted using antibodies against IDH1-R132H and Ki-67 on 11 surgical and autopsy specimens of the tumor core and the invading area. Higher numbers of IDH1-R132H-positive cells in the invading area correlated with a higher tumor grade. Double staining for IDH1-R132H and Ki-67 demonstrated that most invading cells that expressed IDH1-R132H were not stained by the Ki-67 antibody, and the ratio of Ki-67-positive cells among IDH1-R132H-positive cells was significantly lower in the invasion area than in the tumor core in all grades of glioma. These data suggest that higher grade gliomas have a greater invasive potential and that invading cells possess low proliferative capacity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24384677     DOI: 10.1007/s10014-013-0172-y

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  9 in total

Review 1.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

2.  Modeling mayhem: predicting invasion and proliferation kinetics in IDH1 mutant glioblastoma with mathematical models.

Authors:  Justin D Lathia
Journal:  Neuro Oncol       Date:  2014-04-15       Impact factor: 12.300

3.  Natural history of lesions with the MR imaging appearance of multinodular and vacuolating neuronal tumor.

Authors:  Reema Alsufayan; Paula Alcaide-Leon; Lyne Noel de Tilly; Daniel M Mandell; Timo Krings
Journal:  Neuroradiology       Date:  2017-07-27       Impact factor: 2.804

4.  Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.

Authors:  Wen-Yuan Lee; Kuan-Chung Chen; Hsin-Yi Chen; Calvin Yu-Chian Chen
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

5.  Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype.

Authors:  Sune Munthe; Stine Asferg Petterson; Rikke Hedegaard Dahlrot; Frantz Rom Poulsen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

6.  Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.

Authors:  Satoshi Ogasawara; Yuki Fujii; Mika K Kaneko; Hiroharu Oki; Hemragul Sabit; Mitsutoshi Nakada; Hiroyoshi Suzuki; Koichi Ichimura; Takashi Komori; Yukinari Kato
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2016-10

7.  IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.

Authors:  Huixia Zhu; Ye Zhang; Jianfeng Chen; Jiangdong Qiu; Keting Huang; Mindan Wu; Chunlin Xia
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

8.  Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP.

Authors:  Shuang Wei; Jie Wang; Olutobi Oyinlade; Ding Ma; Shuyan Wang; Lisa Kratz; Bachchu Lal; Qingfu Xu; Senquan Liu; Sagar R Shah; Hao Zhang; Yunqing Li; Alfredo Quiñones-Hinojosa; Heng Zhu; Zhi-Yong Huang; Linzhao Cheng; Jiang Qian; Shuli Xia
Journal:  Oncogene       Date:  2018-05-30       Impact factor: 9.867

9.  CircRNA ZNF609 promotes the growth and metastasis of thyroid cancer in vivo and in vitro by downregulating miR-514a-5p.

Authors:  Ping Shi; Yan Liu; Dongqiang Yang; Yanzhao Wu; Lan Zhang; Shanghua Jing; Huijing Shi; Cuizhi Geng
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.